CRSP vs. BMRN
CRSP (CRISPR Therapeutics AG) and BMRN (BioMarin Pharmaceutical Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CRSP returned -13.88%/yr vs -7.17%/yr for BMRN. At a 0.40 correlation, their price movements are largely independent.
Performance
CRSP vs. BMRN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRSP achieves a -0.80% return, which is significantly higher than BMRN's -10.28% return.
CRSP
- 1D
- -4.00%
- 1M
- 0.76%
- YTD
- -0.80%
- 6M
- 0.85%
- 1Y
- 40.78%
- 3Y*
- -7.16%
- 5Y*
- -13.88%
- 10Y*
- —
BMRN
- 1D
- -3.11%
- 1M
- -1.37%
- YTD
- -10.28%
- 6M
- -1.06%
- 1Y
- -6.54%
- 3Y*
- -17.03%
- 5Y*
- -7.17%
- 10Y*
- -5.10%
CRSP vs. BMRN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CRSP CRISPR Therapeutics AG | -0.80% | 33.23% | -37.12% | 54.00% | -46.36% | -50.51% | 151.39% | 113.18% | 21.68% | 15.89% |
BMRN BioMarin Pharmaceutical Inc. | -10.28% | -9.58% | -31.83% | -6.83% | 17.14% | 0.75% | 3.71% | -0.70% | -4.51% | 7.64% |
Correlation
The correlation between CRSP and BMRN is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.37 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.43 |
Correlation (All Time) Calculated using the full available price history since Oct 20, 2016 | 0.40 |
Fundamentals
CRSP:
$5.00B
BMRN:
$10.54B
CRSP:
-$6.24
BMRN:
$1.37
CRSP:
1.15K
BMRN:
3.22
CRSP:
2.75
BMRN:
1.70
CRSP:
$4.10M
BMRN:
$3.24B
CRSP:
-$171.17M
BMRN:
$2.46B
CRSP:
-$509.21M
BMRN:
$439.56M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRSP vs. BMRN — Risk / Return Rank
CRSP
BMRN
CRSP vs. BMRN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CRSP | BMRN | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.66 | -0.19 | +0.85 |
Sortino ratioReturn per unit of downside risk | 1.35 | -0.05 | +1.40 |
Omega ratioGain probability vs. loss probability | 1.16 | 0.99 | +0.16 |
Calmar ratioReturn relative to maximum drawdown | 1.03 | -0.36 | +1.39 |
Martin ratioReturn relative to average drawdown | 1.75 | -0.76 | +2.50 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CRSP | BMRN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.66 | -0.19 | +0.85 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.23 | -0.22 | -0.01 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.14 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.23 | 0.11 | +0.12 |
Drawdowns
CRSP vs. BMRN - Drawdown Comparison
The maximum CRSP drawdown since its inception was -85.11%, smaller than the maximum BMRN drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for CRSP and BMRN.
Loading charts...
Drawdown Indicators
| CRSP | BMRN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.11% | -90.58% | +5.47% |
Max Drawdown (1Y)Largest decline over 1 year | -42.25% | -22.49% | -19.76% |
Max Drawdown (3Y)Largest decline over 3 years | -64.91% | -49.83% | -15.08% |
Max Drawdown (5Y)Largest decline over 5 years | -80.68% | -57.64% | -23.04% |
Max Drawdown (10Y)Largest decline over 10 years | — | -62.09% | — |
Current DrawdownCurrent decline from peak | -75.23% | -64.25% | -10.98% |
Average DrawdownAverage peak-to-trough decline | -49.16% | -45.51% | -3.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.84% | 10.80% | +14.04% |
Volatility
CRSP vs. BMRN - Volatility Comparison
CRISPR Therapeutics AG (CRSP) and BioMarin Pharmaceutical Inc. (BMRN) have volatilities of 15.39% and 15.31%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRSP | BMRN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.39% | 15.31% | +0.08% |
Volatility (6M)Calculated over the trailing 6-month period | 42.57% | 27.72% | +14.85% |
Volatility (1Y)Calculated over the trailing 1-year period | 61.70% | 34.52% | +27.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 60.49% | 32.85% | +27.64% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 64.29% | 35.51% | +28.78% |
Dividends
CRSP vs. BMRN - Dividend Comparison
Neither CRSP nor BMRN has paid dividends to shareholders.
Financials
CRSP vs. BMRN - Financials Comparison
This section allows you to compare key financial metrics between CRISPR Therapeutics AG and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CRSP and BMRN have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRSP has higher volatility (15.39%) compared to BMRN (15.31%). In terms of maximum drawdown, CRSP dropped -85.11% vs BMRN's -90.58%.
CRSP currently has the higher Sharpe Ratio (0.66 vs -0.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRSP and BMRN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer